PURPOSE: Carbonic anhydrase 9 (CA9) is over-expressed in many human solid tumors under conditions of low oxygen concentration and can be associated with a low probability of survival. In this study, stable CA9-expressing cell lines were established using the CA9 gene-defective human C33a cell line and the HeLa cell line to investigate the role of CA9 in response to ionizing radiation and hypoxia-selective cytotoxin, Tirapazamine (TPZ). METHODS AND MATERIALS: Human CA9 cDNA or an empty vector was transfected into the C33a and HeLa cell lines and C33a-vector, C33a-CA9, HeLa-vector, and HeLa-CA9 cell lines were produced accordingly. Sensitivity of the C33a-vector/C33a-CA9 cells to ionizing radiation and TPZ was measured using clonogenic assays. The alkaline comet assay was used to measure single strand DNA breaks caused by TPZ in the C33a-vector, C33a-CA9, HeLa-vector, and HeLa-CA9 cell lines. RESULTS: Radiation sensitivity, as determined with clonogenic survival assays, of C33a-vector/C33a-CA9 cells did not differ under either normoxic or hypoxic conditions. However, increased clonogenic sensitivity to TPZ was observed in C33a-CA9 cells under the hypoxic condition by 26% (95% CI 14-39%, P = 0.02 in comparison to the C33a-vector cells). The comet assay showed significantly greater DNA damage in the C33a-CA9 cells compared with that of the C33a-vector cells with the same treatment under hypoxic conditions, supporting the results of the clonogenic survival data. Because this difference in the amount of DNA damage was not observed for the hypoxic HeLa-CA9/HeLa-vector cell lines, both of which have induced CA9 expression by hypoxia, the enhanced sensitivity of C33a-CA9 cells to TPZ is considered to be due to the specific condition of CA9 over-expression. CONCLUSION: Our results suggest the possibility that CA9 over-expression in tumors might be exploited to increase the treatment effects of TPZ.
PURPOSE:Carbonic anhydrase 9 (CA9) is over-expressed in many human solid tumors under conditions of low oxygen concentration and can be associated with a low probability of survival. In this study, stable CA9-expressing cell lines were established using the CA9 gene-defective human C33a cell line and the HeLa cell line to investigate the role of CA9 in response to ionizing radiation and hypoxia-selective cytotoxin, Tirapazamine (TPZ). METHODS AND MATERIALS: HumanCA9 cDNA or an empty vector was transfected into the C33a and HeLa cell lines and C33a-vector, C33a-CA9, HeLa-vector, and HeLa-CA9 cell lines were produced accordingly. Sensitivity of the C33a-vector/C33a-CA9 cells to ionizing radiation and TPZ was measured using clonogenic assays. The alkaline comet assay was used to measure single strand DNA breaks caused by TPZ in the C33a-vector, C33a-CA9, HeLa-vector, and HeLa-CA9 cell lines. RESULTS: Radiation sensitivity, as determined with clonogenic survival assays, of C33a-vector/C33a-CA9 cells did not differ under either normoxic or hypoxic conditions. However, increased clonogenic sensitivity to TPZ was observed in C33a-CA9 cells under the hypoxic condition by 26% (95% CI 14-39%, P = 0.02 in comparison to the C33a-vector cells). The comet assay showed significantly greater DNA damage in the C33a-CA9 cells compared with that of the C33a-vector cells with the same treatment under hypoxic conditions, supporting the results of the clonogenic survival data. Because this difference in the amount of DNA damage was not observed for the hypoxic HeLa-CA9/HeLa-vector cell lines, both of which have induced CA9 expression by hypoxia, the enhanced sensitivity of C33a-CA9 cells to TPZ is considered to be due to the specific condition of CA9 over-expression. CONCLUSION: Our results suggest the possibility that CA9 over-expression in tumors might be exploited to increase the treatment effects of TPZ.
Authors: Stephen K Williamson; John J Crowley; Primo N Lara; Jason McCoy; Derick H M Lau; Robert W Tucker; Glenn M Mills; David R Gandara Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: S Ivanov; S Y Liao; A Ivanova; A Danilkovitch-Miagkova; N Tarasova; G Weirich; M J Merrill; M A Proescholdt; E H Oldfield; J Lee; J Zavada; A Waheed; W Sly; M I Lerman; E J Stanbridge Journal: Am J Pathol Date: 2001-03 Impact factor: 4.307
Authors: Robert I Haddad; Lisa J Weinstein; Tad J Wieczorek; Nandita Bhattacharya; Harry Raftopoulos; Martin W Oster; Xinxin Zhang; Vaughan M Latham; Rosemary Costello; Jarrod Faucher; Carolyn DeRosa; Murray Yule; Linda P Miller; Massimo Loda; Marshall R Posner; Geoffrey I Shapiro Journal: Clin Cancer Res Date: 2004-07-15 Impact factor: 12.531
Authors: Bronwyn G Siim; Frederik B Pruijn; Joanna R Sturman; Alison Hogg; Michael P Hay; J Martin Brown; William R Wilson Journal: Cancer Res Date: 2004-01-15 Impact factor: 12.701
Authors: Joo-Young Kim; C M L West; H Valentine; T H Ward; A V Patterson; I J Stratford; S A Roberts; J H Hendry Journal: Radiother Oncol Date: 2004-03 Impact factor: 6.280
Authors: Bo Hong; Vivian W Y Lui; Edwin P Hui; Margaret H L Ng; Suk-Hang Cheng; Fion L Sung; Chi-Man Tsang; Sai-Wah Tsao; Anthony Tak-Cheung Chan Journal: Invest New Drugs Date: 2009-12-16 Impact factor: 3.850
Authors: Arup Bhattacharya; Károly Tóth; Farukh A Durrani; Shousong Cao; Harry K Slocum; Sreenivasulu Chintala; Youcef M Rustum Journal: Neoplasia Date: 2008-08 Impact factor: 5.715
Authors: Julia Ling-Yu Chen; Joseph E Lucas; Thies Schroeder; Seiichi Mori; Jianli Wu; Joseph Nevins; Mark Dewhirst; Mike West; Jen-Tsan Chi Journal: PLoS Genet Date: 2008-12-05 Impact factor: 5.917